View in EDS HTML Full Text

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research.

Saved in:
Bibliographic Details
Title: Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research.
Authors: Rougier P (AUTHOR), Sahmoud T (AUTHOR), Nitti D (AUTHOR), Curran D (AUTHOR), Doci R (AUTHOR), De Waele B (AUTHOR), Nakajima T (AUTHOR), Rauschecker H (AUTHOR), Labianca R (AUTHOR), Pector J (AUTHOR), Marsoni S (AUTHOR), Apolone G (AUTHOR), Lasser P (AUTHOR), Couvreur ML (AUTHOR), Wils J (AUTHOR), Rougier, P (AUTHOR), Sahmoud, T (AUTHOR), Nitti, D (AUTHOR), Curran, D (AUTHOR), Doci, R (AUTHOR)
Source: Lancet. 6/6/1998, Vol. 351 Issue 9117, p1677-1681. 5p.
Abstract: Background: There is conflicting evidence on the efficacy of regional adjuvant chemotherapy, via portal-vein infusion (PVI), after resection of colorectal cancer. We undertook a randomised controlled multicentre trial to investigate the efficacy of PVI (500 mg/m2 fluorouracil plus 5000 IU heparin daily for 7 days).Methods: 1235 of about 1500 potentially eligible patients were randomly assigned surgery plus PVI or surgery alone (control). The patients were followed up for a median of 63 months, with yearly screening for recurrent disease. The primary endpoint was survival; analyses were by intention to treat.Findings: 619 patients in the control group and 616 in the PVI group met eligibility criteria. 164 (26%) control-group patients and 173 (28%) PVI-group patients died. 5-year survival did not differ significantly between the groups (73 vs 72%; 95% Cl for difference -6 to 4). The control and PVI groups were also similar in terms of disease-free survival at 5 years (67 vs 65%) and the number of patients with liver metastases (79 vs 77%).Interpretation: PVI of fluorouracil, at a dose of 500 mg/m2 for 7 days, cannot be recommended as the sole adjuvant treatment for high-risk colorectal cancer after complete surgical excision. However, these results cannot eliminate a small benefit when PVI is used at a higher dosage or in combination with mitomycin. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 107268897
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Rougier+P%22">Rougier P</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sahmoud+T%22">Sahmoud T</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nitti+D%22">Nitti D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Curran+D%22">Curran D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Doci+R%22">Doci R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+Waele+B%22">De Waele B</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nakajima+T%22">Nakajima T</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rauschecker+H%22">Rauschecker H</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Labianca+R%22">Labianca R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pector+J%22">Pector J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marsoni+S%22">Marsoni S</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Apolone+G%22">Apolone G</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lasser+P%22">Lasser P</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Couvreur+ML%22">Couvreur ML</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wils+J%22">Wils J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rougier%2C+P%22">Rougier, P</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sahmoud%2C+T%22">Sahmoud, T</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nitti%2C+D%22">Nitti, D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Curran%2C+D%22">Curran, D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Doci%2C+R%22">Doci, R</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 6/6/1998, Vol. 351 Issue 9117, p1677-1681. 5p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>There is conflicting evidence on the efficacy of regional adjuvant chemotherapy, via portal-vein infusion (PVI), after resection of colorectal cancer. We undertook a randomised controlled multicentre trial to investigate the efficacy of PVI (500 mg/m2 fluorouracil plus 5000 IU heparin daily for 7 days).<bold>Methods: </bold>1235 of about 1500 potentially eligible patients were randomly assigned surgery plus PVI or surgery alone (control). The patients were followed up for a median of 63 months, with yearly screening for recurrent disease. The primary endpoint was survival; analyses were by intention to treat.<bold>Findings: </bold>619 patients in the control group and 616 in the PVI group met eligibility criteria. 164 (26%) control-group patients and 173 (28%) PVI-group patients died. 5-year survival did not differ significantly between the groups (73 vs 72%; 95% Cl for difference -6 to 4). The control and PVI groups were also similar in terms of disease-free survival at 5 years (67 vs 65%) and the number of patients with liver metastases (79 vs 77%).<bold>Interpretation: </bold>PVI of fluorouracil, at a dose of 500 mg/m2 for 7 days, cannot be recommended as the sole adjuvant treatment for high-risk colorectal cancer after complete surgical excision. However, these results cannot eliminate a small benefit when PVI is used at a higher dosage or in combination with mitomycin. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=107268897
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 1677
    Titles:
      – TitleFull: Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rougier P
      – PersonEntity:
          Name:
            NameFull: Sahmoud T
      – PersonEntity:
          Name:
            NameFull: Nitti D
      – PersonEntity:
          Name:
            NameFull: Curran D
      – PersonEntity:
          Name:
            NameFull: Doci R
      – PersonEntity:
          Name:
            NameFull: De Waele B
      – PersonEntity:
          Name:
            NameFull: Nakajima T
      – PersonEntity:
          Name:
            NameFull: Rauschecker H
      – PersonEntity:
          Name:
            NameFull: Labianca R
      – PersonEntity:
          Name:
            NameFull: Pector J
      – PersonEntity:
          Name:
            NameFull: Marsoni S
      – PersonEntity:
          Name:
            NameFull: Apolone G
      – PersonEntity:
          Name:
            NameFull: Lasser P
      – PersonEntity:
          Name:
            NameFull: Couvreur ML
      – PersonEntity:
          Name:
            NameFull: Wils J
      – PersonEntity:
          Name:
            NameFull: Rougier, P
      – PersonEntity:
          Name:
            NameFull: Sahmoud, T
      – PersonEntity:
          Name:
            NameFull: Nitti, D
      – PersonEntity:
          Name:
            NameFull: Curran, D
      – PersonEntity:
          Name:
            NameFull: Doci, R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 06
              Text: 6/6/1998
              Type: published
              Y: 1998
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 351
            – Type: issue
              Value: 9117
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1